GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Meropenem / vaborbactam (Vabomere)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug4 sources available - open source summaries, references and comparisons

Vabomere

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Renal-band endpoints differ between the label mirror and UCSF

Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.

Before applying: Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.

Also check: Renal-band endpoints differ between the label mirror and UCSF

Official source

VABOMERE - adult U.S. label

Product / population
Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.
Renal measure
MDRD eGFR indexed to 1.73 m2.

Dosing / renal protocol and limits

For adult complicated UTI including pyelonephritis, infuse each dose over 3 hours; label treatment duration is up to 14 days.

MDRD eGFR (mL/min/1.73 m2)Total combination doseInterval
>=504 g (2 g meropenem + 2 g vaborbactam)Every 8 hours
30-492 g (1 g + 1 g)Every 8 hours
15-292 g (1 g + 1 g)Every 12 hours
<151 g (0.5 g + 0.5 g)Every 12 hours

Give renal-adjusted doses after HD. The label uses indexed MDRD eGFR, not unindexed Cockcroft-Gault CrCl. Do not apply a meropenem-alone regimen to this combination.

Source revision: DailyMed updated 2026-02-27. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

VABOMERE - adult U.S. label

Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: MDRD eGFR indexed to 1.73 m2.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Vabomere

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult IV VABOMERE for complicated urinary tract infection, including pyelonephritis; amounts are combined meropenem plus vaborbactam.

Renal method: Indexed eGFR, mL/min/1.73 m2; the retrieved label specifies MDRD.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF - VABOMERE

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF: meropenem/vaborbactam renal and dialysis tables

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

UCSF adult institutional all-indications table; not a replacement for exact labeled indication and boundaries.

Renal method: Indexed eGFR in mL/min/1.73 m2; intermittent and continuous hemodialysis.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

ambiguous threshold

Renal-band endpoints differ between the label mirror and UCSF

Both tables use indexed eGFR, but the label assigns exactly 50 to its full-dose band, whereas UCSF prints >50 and 30-50. UCSF also prints overlapping bands at exactly 30. The dialysis and indication scopes are separately stated.

How to use this: Do not silently round an estimate, substitute unindexed CrCl, average doses, or combine one source's band with another interval. Clarify boundary cases with the applicable label and institutional antimicrobial team.

GlobalRPh RX List - VabomereUCSF: meropenem/vaborbactam renal and dialysis tables

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeVABOMERE - adult U.S. labelGlobalRPh RX List - VabomereUCSF - VABOMEREUCSF: meropenem/vaborbactam renal and dialysis tables
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Both the U.S. label and UCSF use indexed eGFR for this combination. Their printed renal-band boundaries differ: the UCSF bands overlap at 30 and place 50 in a different printed band. Retain the selected source boundary explicitly; do not treat an overlap as an instruction to combine regimens.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d

Product and population scope

Adult Meropenem / vaborbactam (Vabomere). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-meropenem-vaborbactam · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

VABOMERE - adult U.S. label

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: MDRD eGFR indexed to 1.73 m2.
Source date: DailyMed updated 2026-02-27.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adult complicated UTI including pyelonephritis, infuse each dose over 3 hours; label treatment duration is up to 14 days.

MDRD eGFR (mL/min/1.73 m2)Total combination doseInterval
>=504 g (2 g meropenem + 2 g vaborbactam)Every 8 hours
30-492 g (1 g + 1 g)Every 8 hours
15-292 g (1 g + 1 g)Every 12 hours
<151 g (0.5 g + 0.5 g)Every 12 hours

Give renal-adjusted doses after HD. The label uses indexed MDRD eGFR, not unindexed Cockcroft-Gault CrCl. Do not apply a meropenem-alone regimen to this combination.

RDM30-069-meropenem-vaborbactam-1 · Source locator: VABOMERE - adult U.S. label; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d
Retrieved
2026-09-05
DailyMed Set ID
e237fd0f-3050-42a3-b43e-b6fb4824e93d
Renal-function method
MDRD eGFR indexed to 1.73 m2.
Source date/version
DailyMed updated 2026-02-27.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e84ba89a936c00cf8575e5b1f878a7c77c3e663e2799b458852d7510ed05056a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Vabomere

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult IV VABOMERE for complicated urinary tract infection, including pyelonephritis; amounts are combined meropenem plus vaborbactam.

Renal method: Indexed eGFR, mL/min/1.73 m2; the retrieved label specifies MDRD.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Infuse each dose over three hours. At eGFR >=50, the adult regimen is 4 g (2 g of each component) every eight hours. At 30-49 use 2 g every eight hours; at 15-29 use 2 g every twelve hours; below 15 use 1 g every twelve hours. The reduced 2 g and 1 g doses contain equal amounts of both components. Give after hemodialysis on dialysis days. With changing kidney function, reassess creatinine and eGFR at least daily and adjust accordingly. The source uses indexed eGFR, not unindexed Cockcroft-Gault clearance. Its historical race-containing equation is not implemented in this tool.

RDM40-rxlist-meropenem-vaborbactam-e6fa208812-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/vabomere-drug/
Retrieved
2026-09-07
Renal-function method
Indexed eGFR, mL/min/1.73 m2; the retrieved label specifies MDRD.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
dea4f6f7f6d16f0a032757b23bcc4bc93ff46b6561c653a2ca0285b40d9088ad
Separate professional-source layer

University and professional protocols

Professional

UCSF - VABOMERE

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Four grams contains 2 g of each component. Printed columns overlap at exactly 30. Use an adjudicated boundary rather than merging rows.

Total combination amount - IV over 3 hours
Indexed eGFR, mL/min/1.73 m2Source-specific dose / instruction
>504 g every 8 hours
30-502 g every 8 hours
15-302 g every 12 hours
<151 g every 12 hours
Dialysis guidance - separate source-specific schedules
Meropenem/vaborbactam dialysis
Dialysis setting / indicationSource-specific schedule
IHD1 g every 12 hours; one dose after dialysis on HD days
CVVHD2 g every 8 hours
Read the retained text before reformatting

Total combination dosing (4 g contains 2 g of each component), with 3-hour IV infusions:

Indexed eGFR >50 / 30-50 / 15-30 / <15 mL/min/1.73 m2 corresponds to 4 g every 8 hours / 2 g every 8 hours / 2 g every 12 hours / 1 g every 12 hours.

The website columns overlap at exactly 30; select an adjudicated label/institutional boundary rather than blending the two rows.

IHD: 1 g every 12 hours, placing one dose after dialysis on HD days. CVVHD: 2 g every 8 hours.

RDM30-008-meropenem-vaborbactam-1 · Source locator: UCSF - VABOMERE; renal/dosing sections and stated qualifiers

Source-specific limits

The published UCSF renal bands overlap at 30. The exact label is displayed separately.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/meropenem-vaborbactam
Retrieved
2026-09-05
Renal-function method
Indexed eGFR in mL/min/1.73 m2, not unindexed Cockcroft-Gault CrCl.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
2959e7ac949a91b4d4d149260ce1f8df090b9798ff43d046b3360caf474f901b
Professional

UCSF: meropenem/vaborbactam renal and dialysis tables

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · UCSF adult institutional all-indications table; not a replacement for exact labeled indication and boundaries.

Renal method: Indexed eGFR in mL/min/1.73 m2; intermittent and continuous hemodialysis.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The displayed eGFR bands are >50, 30-50, 15-30 and <15. Corresponding combined doses are 4 g every eight hours, 2 g every eight hours, 2 g every twelve hours and 1 g every twelve hours, each IV over three hours. Exactly 30 overlaps two source rows; exactly 50 also differs from the label boundary. Intermittent HD uses 1 g every twelve hours with one dose after HD on dialysis days. Continuous HD uses 2 g every eight hours. Restricted specialist use is specified. Do not silently round or merge source boundaries.

RDM40-professional-meropenem-vaborbactam-f6a38d7cf6-C1 · Source locator: Adult eGFR table and intermittent/continuous-HD table

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/meropenem-vaborbactam
Retrieved
2026-09-07
Renal-function method
Indexed eGFR in mL/min/1.73 m2; intermittent and continuous hemodialysis.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
048ad44191fa6c69b2d5c502bb245e6eb36359cdaa6f863737f43086ce955984

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 2 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e237fd0f-3050-42a3-b43e-b6fb4824e93d
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
8a871f6c52df8540d347989f4ae0cd7da4558e0111d5bc94e054d2754bdaadea
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report